Clinical Trials in China / NCT05876065
Recruiting
Not applicable
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
NCT05876065 · tracked via the Priya Life Science China tracker
Condition(s) studied
Advanced Breast Cancer
Investigational drug(s) / intervention(s)
XCTPC
XC: Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days
TPC: Any physician's choice as maintenance therapy (except for XC regimen)
Study summary
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
Eligibility
Inclusion Criteria:
* Female, age≥18 years old
* ECOG≤2
* Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions
* HR+/HER2+ or HR-/HER2+ or HR-/HER2-
* At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
* Disease control (complete response + partial response + stable disease) after salvage treatment
* Expected survival ≥6 months
* Adequate organ function
Exclusion Criteria:
* during pregnancy and lactation
* Patients with central nervous system metastasis
Primary outcome measure(s)
- Progression-Free Survival (PFS) — From the date of starting maintenance therapy to the date of first documentation of disease progression or death from any cause (up to approximately 1 year)
PFS is defined as the time from the date of starting maintenance therapy to the date of disease progression or death from any cause, whichever occurs first.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University | Shanghai | China | Recruiting |
More Wenjin Yin trials in China
The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis
Active, not recruiting
The Association Between Blood Routine Parameters and Breast Cancer Prognosis
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05876065 on ClinicalTrials.gov ↗ ← All trials in China